



HAL
open science

The chemokine CXCL13 in acute neuroborreliosis

Makbule Senel, Tobias A Rupprecht, Hayrettin Tumani, Hans Walter Pfister,
Albert C Ludolph, Johannes Brettschneider

► **To cite this version:**

Makbule Senel, Tobias A Rupprecht, Hayrettin Tumani, Hans Walter Pfister, Albert C Ludolph, et al.. The chemokine CXCL13 in acute neuroborreliosis. *Journal of Neurology, Neurosurgery and Psychiatry*, 2009, 81 (8), jnnp.2009.195438v1. 10.1136/jnnp.2009.195438 . hal-00557426

HAL Id: hal-00557426

<https://hal.science/hal-00557426>

Submitted on 19 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The chemokine CXCL13 in acute neuroborreliosis

Makbule Senel¹, Tobias A. Rupprecht, MD², Hayrettin Tumani H, MD^{1†}, Hans W. Pfister, MD²,
Albert C. Ludolph, MD¹, Johannes Brettschneider, MD¹.

¹Dept. of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm

²Dept. of Neurology, Ludwig-Maximilians-University of Munich-Grosshadern

†Corresponding author: Hayrettin Tumani, MD, Dept. of Neurology, Univ. of Ulm, Oberer Eselsberg
45, 89081 Ulm, Germany, Tel.: +49-731 177 5204; Fax: +49-731-177 1519; e-mail:

hayrettin.tumani@uni-ulm.de

Word count manuscript: 2640 words (without abstract and references, including tables)

Keywords: neuroborreliosis – chemokines – CXCL13 – cerebrospinal fluid – disease activity

ABSTRACT

Objective: Recent studies have suggested an important role of the B-cell chemoattractant CXCL13 in acute neuroborreliosis (NB). Our aim was to confirm the diagnostic role of CXCL13 and to evaluate its relevance as a therapy response and disease activity marker in NB.

Methods: CXCL13 was measured in cerebrospinal fluid (CSF) and serum of patients with NB (NB, n= 28), systemic borreliosis (SB, n=9), Guillain-Barré syndrome (GBS, n=11), Bell's palsy (BP, n=19), other cranial nerve palsies (CNP, n=5), cephalgia (C, n=20), bacterial-CNS-infections (B-CNS-I, n=16) and from patients with viral-CNS-infections (V-CNS-I, n=18). For follow-up studies serial sample pairs were evaluated from 25 patients with NB (n=56), 11 with B-CNS-I (n=25) and 14 with V-CNS-I (n=36).

Results: CSF-CXCL13 was significantly elevated in NB compared to other neurological diseases ($p<0.001$). Using ROC analysis, 337 ng/g was determined as cut-off with a sensitivity of 96.4 % and a specificity of 96.9 %. Of all the parameters investigated, CSF CXCL13 showed the fastest response to antibiotic therapy, decreasing significantly ($p=0.008$) within one week. In untreated patients, CSF CXCL13 was elevated in patients with a short duration of disease. Borrelia burgdorferi antibody index (BB-AI) showed no significant ($p=0.356$) change over follow-up.

Conclusions: Our study confirms the relevance of CXCL13 as a diagnostic biomarker of NB. It suggests that CSF CXCL13 in NB is linked to duration of disease and could be a marker of disease activity and response to antibiotic therapy.

INTRODUCTION

Neuroborreliosis (NB) is a nervous system manifestation of Lyme borreliosis, caused by the tick-borne spirochete *Borrelia burgdorferi* (BB).[1-4] Due to a great variety of neurological symptoms such as meningitis, meningoradiculitis, or cranial nerve palsies,[5, 6] identification of neuroborreliosis frequently is a diagnostic challenge in clinical neurology. Currently the method of choice for the diagnosis of acute NB is the combined analysis of basic cerebrospinal fluid (CSF) parameters (lymphocytic pleocytosis, intrathecal synthesis of immunoglobulins and/ or blood-CSF barrier dysfunction) and determination of BB specific antibody index (BB-AI ≥ 1.5 , i.e. intrathecal antibody synthesis to BB).[7] However, this approach has important limitations: (1) Elevated basic CSF variables are also found in various other inflammatory diseases of the central nervous system (CNS).[8, 9] (2) Intrathecal BB antibody synthesis may not be detectable in early stages of disease, especially if disease duration is less than 2-3 weeks.[10-14] (3) Elevated BB-AI does not discriminate between active and past infections as it is known to persist for years in spite of successful treatment.[14] (4) False positive results may occur due to antibody cross reactivities.[10, 15, 16] (5) Due to the use of different isolates as antigen in various immunosorbent assays for BB antibodies, results may vary considerably among different laboratories.

Recent studies have suggested an important role of CXCL13 in the diagnosis of NB.[17, 18] CXCL13 belongs to the CXC chemokine family and is a selective chemoattractant for B-lymphocytes and B-helper T-cells via the chemokine receptor CXCR5.[19] Our aim was to confirm the diagnostic value of CXCL13 in NB in comparison to established diagnostic parameters such as BB-AI and to evaluate the relevance of CXCL13 as a marker of disease activity and therapy response in acute NB.

METHODS

Patients

Table 1: Demographic data and basic CSF findings of patients included in this study. Data are shown as median and interquartile range; NB = neuroborreliosis, SB= systemic borreliosis, B-CNS-D = bacterial infections of the central nervous system, V-CNS-D = viral infections of the central nervous system, C = cephalgia, GBS = Guillain-Barré syndrome, CNP = cranial nerve palsies, BP = Bell's palsy. Qalb = CSF/serum albumin concentration ratio, IgM synthesis is intrathecal IgM synthesis, OCB = oligoclonal IgG bands.

	n (f/m)	Age [years]	Cell count [/μl]	Qalb (x 10 ⁻³)	IgM synthesis [%]	OCB [%]
NB	28 (9/19)	58 (32-70)	84 (50-187)	13.8 (9.7-23.3)	78.6	85.7
SB	9 (1/8)	44 (40-56)	1 (1-4)	6.6 (4.6-8.3)	22.2	11.1
B-CNS-D	16 (9/7)	53 (36-69)	2134 (117-4682)	58.1 (35.5-90.2)	18.8	13.3
V-CNS-D	18 (3/15)	38 (27-63)	178 (54-290)	11.8 (8.8-16.7)	16.7	22.2
C	20 (10/10)	53 (44-64)	1 (0-2)	4.8 (3.7-7.1)	0	0
GBS	11 (4/7)	40 (27-51)	1 (0-2)	17.4 (6.8-23.2)	9.1	63.6
CNP	5 (1/4)	65 (54-66)	2 (1-2)	6.2 (5.7-8.4)	0	0
BP	19 (11/8)	40 (26-67)	2 (1-3)	5.2 (4.4-6.0)	0	15.8

Drawing of blood and lumbar puncture was performed for diagnostic purposes after the patient's informed consent was obtained. Paired CSF and serum samples were collected between January 2000 and September 2008 from 126 patients admitted to the Department of Neurology, University of Ulm, Germany (for demographic data, see table 1). Patients included 28 patients with definite neuroborreliosis (NB) according to criteria by Kaiser[7] and 9 patients with systemic borreliosis (SB) who showed no clinical signs of neuroborreliosis and showed normal basic CSF findings (including cell count, total protein and lactate). At time of lumbar puncture, none of the NB patients received any antibiotic therapy. Furthermore, we included 69 patients with neurological diseases relevant in the differential diagnosis of NB, comprising of 16 patients with bacterial infections of the CNS (B-CNS-D, including meningitis or meningoencephalitis caused by *Treponema pallidum*, *Mycobacterium tuberculosis*, *Streptococcus pneumoniae*, *Meningococcus*, *Listeria monocytogenes*, *Haemophilus influenzae*, *Staphylococcus aureus* or other Streptococci), 18 patients with viral CNS diseases (V-CNS-D, including meningitis or meningoencephalitis caused by *herpes simplex virus (HSV)*, *varicella zoster virus (VZV)*, *Epstein-Barr virus (EBV)*, *rubella virus*, *tick-borne encephalitis Virus (TBEV)*, *enterovirus*), 11 patients with Guillain-Barré syndrome (GBS), 19 patients with Bell's palsy (BP) and 5 patients with other cranial nerve palsies (CNP). As normal controls, we included 20 patients with cephalgia (C) who presented with tension-type headache and showed no evidence of a structural, hemorrhagic or inflammatory lesion.

For follow-up studies we included serial CSF/Serum sample pairs from 25 patients with NB (n=56), 11 patients with bacterial (n=25) and 14 patients with viral (n=36) infections of the CNS. Samples of eight of these NB patients were obtained from the Department of Neurology, Ludwig-Maximilians University, Munich, Germany. Standard antibiotic therapy of NB patients consisted of ceftriaxone 2 g intravenously per day over 2 weeks.

CSF analysis and CXCL13 assay

All CSF samples were stored at -80°C until analysis. CSF leukocyte count (cells/cu.mm), total protein (g/L), lactate (mmol/L), CSF/serum albumin concentration ratio (Q_{alb}), immunoglobulin (Ig) G, A and M and oligoclonal IgG bands (OCB) were obtained as previously described.[20] Intrathecal synthesis of antibodies to BB was determined by calculation of the specific antibody indices (AI): $\text{AI} = Q_{\text{Ig[spec]}}/Q_{\text{Ig[total]}}$, if $Q_{\text{Ig[total]}} < Q_{\text{lim}}$, and $\text{AI} = Q_{\text{Ig[spec]}}/Q_{\text{lim}}$, if $Q_{\text{Ig[total]}} > Q_{\text{lim}}$. [21] The upper reference range of $Q_{\text{Ig[total]}}$, Q_{lim} , was calculated according to Reiber's formula. AI values ≥ 1.5 were considered to be indicative of intrathecal Ig synthesis against BB (Reiber 1998).[21]

CXCL13 was measured by quantitative enzyme-linked immunosorbent assay (ELISA) (Quantikine; R&D Systems, Minneapolis, MN) according to the instructions as supplied by the manufacturer. For validating and assessing assay accuracy spike-and-recovery as well as linearity-of-dilution experiments were performed. To compensate for differences in CSF protein due to blood-CSF barrier dysfunction in acute NB, CSF CXCL13 was related to total CSF protein in accordance with Rupprecht et al., Neurology 2005.[17] The *Borrelia afzelii*+VlsE IgG ELISA (PKo strain, Genzyme Virotech, Rüsselsheim, Germany) was used for detection of IgG antibodies against BB sensu lato.

Statistical analysis

Statistical analysis was performed using SPSS (version 16.0; SPSS Inc., Chicago, IL, USA). Differences of CXCL13 between groups were analyzed using Kruskal-Wallis test followed by single pairwise comparisons (Mann-Whitney U-test). Wilcoxon signed rank test was applied to compare concentrations at individual time points with baseline (diagnostic LP) values, and Friedman test (repeated measures of ANOVA on ranks) was applied to analyse repeated values for a global analysis of progression. Correlation was analysed using Spearman rank order correlation. To test

for normality, the Kolmogorov-Smirnov-test was applied. Sensitivity was calculated as (true-positive / [true-positive + false-negative]), specificity was calculated as (true-negative / [true-negative + false-positive]). To examine the accuracy of CXCL13 to differentiate NB from controls, we used Receiver operating characteristic (ROC) analysis, calculating the area under the ROC curve (AUROCC). The Youden index was calculated for each cut-off value as corresponding [(sensitivity + specificity) – 1] to find the cut-off values which maximize discriminating accuracy.[22] P values < 0.05 were considered as statistically significant.

RESULTS

Clinical findings and basic CSF examination results

At time of diagnosis, the mean duration of symptoms in NB patients was 11 days (median 7; range 1 to 40). Only 32.1% of patients (9 of 28) remembered a tick bite. The most frequent neurological symptoms in NB patients were polyradiculitis (9 of 28) and facial nerve palsy (10 of 28). In CSF, all patients with NB showed a lymphocytic pleocytosis and most of the patients (82 %) revealed increased CSF protein measured by an elevation of Q_{alb} (table 1). Intrathecal IgM synthesis was found in 78%, while IgG and IgA synthesis were observed in 35.7 % (table 1). All NB patients showed elevated BB-IgG-AI (≥ 1.5), with a median AI of 17 (range 2.6-104, table 1).

Assay validation

ELISA matrix spike recovery was acceptable, with an average recovery of 100% and a range in spike recoveries of 93-109% (n=9). Linearity-of-dilution experiments showed an average recovery of 102.5 % (range 98–109 n=6). According to linearity-of-dilution experiments concentrations < 3.9 pg/ml were stated as not detectable.

CXCL13 at diagnostic lumbar puncture

Patients with NB showed significantly elevated CSF CXCL13 levels as compared to all other groups ($p=0.001$, figure 1). NB patients with a shorter duration of disease (≤ 8 days) showed significantly higher CSF-CXCL13 concentrations as compared to patients with a longer duration of disease (> 8 days) (pair wise comparison, $p=0.016$; scatterplot, figure 3). Higher CSF CXCL-13 concentrations in those patients tended to be associated with higher CSF leukocyte count ($p = 0.095$), though this did not reach statistical significance. CSF-CXCL13 correlated with neither Q_{alb} ($R=0.350$ $p=0.068$) nor with serum-CXCL13 ($R=0.372$ $p=0.067$). CSF CXCL13 levels were slightly elevated in single cases of bacterial or viral CNS infections, with highest values being detected in patients with neurosyphilis (NS), *Staphylococcus aureus* meningomyelitis and meningoencephalitis caused by HSV (figure 1). CXCL13 was under the detection limit in most patients with cephalgia, BP, CNP, GBS and patients with SB (figure 1, table 1). Serum-CXCL13 was elevated in B-CNS-D (inclusive NS) but was otherwise not significantly different in NB as compared to controls (figure 2, table1). Highest serum-CXCL13 was observed in patients with pneumococcal or *Haemophilus influenza* infections. The mean CXCL13 CSF/serum ratio in NB was 81.9, which was significantly higher as in all other groups ($p < 0.001$).

Table 2: Accuracy of CSF markers for diagnosis of neuroborreliosis; sensitivity and specificity in percent (95% confidence interval in brackets); basic CSF findings (BCF) = pleocytosis > 4 cells, intrathecal IgM synthesis and/or elevation of Q_{alb} ; BB-AI is $AI \geq 1.5$.

	Sensitivity	Specificity
Basic CSF findings	96.4 (82- 100)	63.3 (53-73)

BB-AI	100 (88- 100)	87.1 (70-97)
BB-AI + BCF	96.4 (82- 100)	90.3 (74- 98)
CXCL13: > 337 ng/g	96.4 (82- 100)	96.9 (91- 99)

ROC analysis was performed to determine cut-off values of CSF-CXCL13 for diagnosis of NB. To discriminate NB from all other groups, the AUROC was 0.98 [95% CI, 0.953-1.004] for CSF CXCL13. Using 337ng/g as cut-off sensitivity and specificity were found to be 96.4 and 96.9 % (table 2). The diagnostic sensitivity and specificity of BB-IgG-AI was 100% and 87.1%. Analysis of combined basic CSF variables (pleocytosis, intrathecal synthesis of IgM and/or blood-CSF barrier dysfunction) showed a sensitivity of 96.4% and a specificity of 63.3% (table 2). Combination of pathological BB-AI and basic CSF variables yielded a sensitivity of 96.4% and a specificity of 90.3% (table 2). CSF-CXCL13 was elevated (>337ng/g) in only three cases with inflammatory CNS reaction not due to BB, including a patient with neurosyphilis, *Staphylococcus aureus* meningomyelitis and HSV meningoencephalitis. Only in one patient with NB CSF CXCL13 was below 337 ng/g. BB-IgG-AI was positive (≥ 1.5) in four patients with diagnoses other than NB.

CXCL13 over follow-up

Two weeks after onset of antibiotic therapy, 41% of NB patients showed a complete remission of symptoms, 53% reported subjective complaints such as pain or paresthesia, and 6% showed objective deficits such as persisting Bell's palsy. CXCL13 showed a significant decrease within one week ($p=0.008$) of onset of antibiotic therapy (figure 4), with CSF CXCL13 levels decreasing below the cut-off after two weeks. In contrast, total CSF leukocyte count decreased significantly ($p=0.009$) only during the second week after onset of antibiotic treatment, though CSF leukocyte

count still remained above the normal level ($>4/\mu\text{l}$) in all patients. BB-AI showed no significant changes over follow-up ($p=0.356$). Of all investigated parameters, CXCL13 showed the fastest and most pronounced decrease after onset of antibiotic therapy. In detail, CSF-CXCL13 fell considerably in all 25 NB- patients whereas CSF leukocyte count (in 28%), albumin ratio (in 12%) and total protein (in 20%) showed even an increase in some patients.

As control groups, we analyzed serial samples from patients with bacterial ($n=11$) and viral ($n=14$) meningitis/meningoencephalitis. CSF CXCL13 levels in bacterial infections of the CNS showed no significant change over follow-up ($p=0.112$) whereas CSF leukocyte count (in 81% of patients), albumin ratio (in all) and lactate (in all) decreased. The CSF CXCL13 levels in viral infections of the CNS showed also no significant change during follow-up ($p=0.448$), as did leukocyte count and Q_{alb} . Serum CXCL13 levels were similar to serum CXCL13 levels of controls.

DISCUSSION

CXCL13 as diagnostic marker in neuroborreliosis

We observed elevated CSF-CXCL13 in NB and neurosyphilis (NS) as compared to other CNS-diseases, which is in line with previous studies.[18, 23, 24] At a cut-off of 337ng/g, CSF-CXCL13 revealed the highest combined sensitivity (96.4%) and specificity (96.9%) for diagnosis of NB of all parameters investigated. Basic CSF findings had an acceptable sensitivity (96.4%) but insufficient specificity (63.3%). Due to our selection criteria of patients with NB sensitivity of BB-AI was 100%, but other studies reported BB-AI to be negative in about 10-20% at early stages of disease activity (disease duration less than 2-3 weeks).[10-14] Furthermore, our data revealed specificity of BB-AI to be comparatively low (87.1%), which may be due to past infections with BB or antibody cross-reactivity with other infectious agents such as *Treponema pallidum*. Combination of BB-AI and

basic CSF variables improved diagnostic accuracy in accordance with previous studies[10] but did not reach diagnostic accuracy of CXCL13.

Only in three patients with diagnosis other than NB elevated CSF-CXCL13 was observed: One patient was diagnosed as HSV encephalitis, one as neurosyphilis and one suffered from *Staphylococcus aureus* meningoencephalitis. We observed no correlation of CSF CXCL13 with either Q_{alb} or serum CXCL13, indicating that CSF CXCL13 is mainly synthesized intrathecally. Serum CXCL13 was not useful for diagnosis of NB but showed elevated levels in patients with B-CNS-D. Consequently, serum-CXCL13 could be useful to differentiate between NB and other B-CNS-D, especially in the case of NS, which was also observed to show elevated CSF-CXCL13 concentrations.[24] The pathophysiological mechanisms underlying this discrepancy of CSF and serum CXCL13 in NB are a matter of speculation. Immune evasion strategies of BB in the blood compartment like downregulation of outer surface proteins (Osp), hiding in extracellular matrix, or the secretion of complement-neutralizing proteins was suggested to reduce the immune response to BB in the peripheral blood and consequently the production of CXCL13 by monocytes and dendritic cells.[25] Furthermore, migration of BB into the CNS along peripheral nerves could also enable BB to avoid the host immune system, resulting in low serum CXCL13 levels.[26, 25] In the nervous system, OspA has been observed to be upregulated again, inducing the secretion of CXCL13 by interaction with the toll-like receptor 2 of monocytes.[25]

CXCL13 as marker of disease activity and duration

Of all the parameters investigated, CSF CXCL13 showed the fastest response to antibiotic therapy with intravenous ceftriaxone, decreasing significantly within one week (figure 4). In contrast, BB-AI showed no significant decrease under therapy, which is in line with previous studies that found BB-AI to persist up to several years after acute NB.[10-14] Accordingly, BB-AI could mimic acute

inflammation with BB, especially in cases of elevated cell count due to an infection with another pathogen. The fast decline under therapy with ceftriaxone suggests that CSF CXCL13 may offer a new tool to measure disease activity in patients with NB. This is in line with a previous study that reported a strong correlation between CXCL13 gene expression and spirochetal load.[27]

However, we also observed high levels of CSF CXCL13 to be related to a short duration of disease prior to lumbar puncture, suggesting that CSF CXCL13 may be a marker of disease duration in NB rather than a marker of disease activity. Future studies including a larger number of patients with follow-up data will have to clarify whether CXCL13 is a marker of disease activity or merely a marker of disease duration in NB.

Conclusion

Our study confirms the relevance of CXCL13 as a diagnostic biomarker of NB. It suggests that CSF CXCL13 levels in NB are linked to duration of disease and could be a marker of disease activity and response to antibiotic therapy. We recommend CSF-CXCL13 to be used for diagnosis of NB in addition to established parameters like BB-AI. Especially in cases with positive BB-AI due to past NB and elevated CSF leukocyte count due to an infection with another pathogen, CSF-CXCL13 is currently the best tool to differentiate between active and past infection with BB.

Acknowledgements

We thank **Dr Vera Lehmensiek and Mrs. Helga Mogel** for **their technical assistance**.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in PMJ and any other

BMJPGJ products and sublicences such use and exploit all subsidiary rights, as set out in our licence. Competing interest: None declared.

REFERENCES

- [1] Burgdorfer W, Barbour AG, Hayes SF, *et al.* Lyme disease-a tick-borne spirochetosis? *Science* 1982;**216**(4552):1317-1319.
- [2] Benach JL, Bosler EM, Hanrahan JP, *et al.* Spirochetes isolated from the blood of two patients with Lyme disease. *N Engl J Med* 1983;**308**(13):740-742.
- [3] Steere AC, Grodzicki RL, Kornblatt AN, *et al.* The spirochetal etiology of Lyme disease. *N Engl J Med* 1983;**308**(13):733-740.
- [4] Pachner AR, Steere AC. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. *Neurology* 1985;**35**(1):47-53.
- [5] Pfister HW, Wilske B, Weber K. Lyme borreliosis: basic science and clinical aspects. *Lancet* 1994;**343**(8904):1013-1016.
- [6] Hengge UR, Tannapfel A, Tying SK, *et al.* Lyme borreliosis. *Lancet Infect Dis* 2003;**3**(8):489-500.
- [7] Kaiser R. Neuroborreliosis. *J Neurol* 1998;**245**(5):247-255.
- [8] Reiber H, Lange P. QUANTIFICATION OF VIRUS-SPECIFIC ANTIBODIES IN CEREBROSPINAL FLUID AND SERUM SENSITIVE AND SPECIFIC DETECTION OF ANTIBODY SYNTHESIS IN BRAIN. *Clin Chem* 1991;**37**(7):1153-1160.

- [9] Felgenhauer K, Reiber H. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. *Clin Investig* 1992;**70**(1):28-37.
- [10] Tumani H, Nolker G, Reiber H. Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. *Neurology* 1995;**45**(9):1663-1670.
- [11] Kaiser R, Rauer S. Analysis of the intrathecal immune response in neuroborreliosis to a sonicate antigen and three recombinant antigens of *Borrelia burgdorferi sensu stricto*. *Eur J Clin Microbiol Infect Dis* 1998;**17**(3):159-166.
- [12] Hansen K, Lebech AM. Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of *Borrelia burgdorferi*--specific immunoglobulin G, A, and M. *Ann Neurol* 1991;**30**(2):197-205.
- [13] Wilske B, Bader L, Pfister HW, *et al*. Diagnosis of Lyme neuroborreliosis. Detection of intrathecal antibody formation. *Fortschr Med* 1991;**109**(22):441-446.
- [14] Hammers-Berggren S, Hansen K, Lebech AM, *et al*. *Borrelia burgdorferi*-specific intrathecal antibody production in neuroborreliosis: a follow-up study. *Neurology* 1993;**43**(1):169-175.
- [15] Hansen K, Cruz M, Link H. Oligoclonal *Borrelia burgdorferi*-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. *J Infect Dis* 1990;**161**(6):1194-1202.
- [16] Stiernstedt GT, Granstrom M, Hederstedt B, *et al*. Diagnosis of spirochetal meningitis by enzyme-linked immunosorbent assay and indirect immunofluorescence assay in serum and cerebrospinal fluid. *J Clin Microbiol* 1985;**21**(5):819-825.
- [17] Rupprecht TA, Pfister HW, Angele B, *et al*. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. *Neurology* 2005;**65**(3):448-450.

- [18] Ljostad U, Mygland A. CSF B--lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. *J Neurol* 2008;**255**(5):732-737.
- [19] Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. *Immunity* 2001;**14**(4):377-386.
- [20] Sussmuth SD, Tumani H, Ecker D, *et al.* Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. *Neurosci Lett* 2003;**353**(1):57-60.
- [21] Reiber H. Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. *Mult Scler* 1998;**4**(3):99-107.
- [22] YODEN WJ. Index for rating diagnostic tests. *Cancer* 1950;**3**(1):32-35.
- [23] Rupprecht TA, Koedel U, Angele B, *et al.* Cytokine CXCL13--a possible early CSF marker for neuroborreliosis. *Nervenarzt* 2006;**77**(4):470-473.
- [24] Rupprecht TA, Kirschning CJ, Popp B, *et al.* *Borrelia garinii* induces CXCL13 production in human monocytes through Toll-like receptor 2. *Infect Immun* 2007;**75**(9):4351-4356.
- [25] Rupprecht TA, Koedel U, Fingerle V, *et al.* The pathogenesis of lyme neuroborreliosis: from infection to inflammation. *Mol Med* 2008;**14**(3-4):205-212.
- [26] Horstrup P, Ackermann R. Tick born meningopolyneuritis (Garin-Bujadoux, Bannwarth) (author's transl). *Fortschr Neurol Psychiatr Grenzgeb* 1973;**41**(11):583-606.
- [27] Narayan K, Dail D, Li L, *et al.* The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. *Ann Neurol* 2005;**57**(6):813-823.

FIGURE LEGENDS


Figure 1: CXCL13 (ng/g protein) in the CSF of neuroborreliosis and other neurological diseases; horizontal solid lines indicate medians. Kruskal-Wallis-test and pair wise comparisons (Mann-Whitney U-test) revealed a significant difference between the groups ($p < 0.001$). Dashed line at 337ng/g represents the cut-off level yielding the highest combined sensitivity and specificity for discriminating patients with NB from those with other diseases. Gray triangle indicates an outlier (neurosyphilis patient) with CSF CXCL13 of 113000 ng/g. y-axis is broken twice; NB = definite neuroborreliosis, SB = systemic borreliosis, B-CNS-D = bacterial CNS disease, V-CNS-D = viral CNS disease, C = cephalgia, GBS = Guillain-Barré-Syndrom, CNP = cranial nerve palsies, BP = Bell's palsy.

Figure 2: Serum CXCL13 (pg/ml) in bacterial-CNS- disease (B-CNS-D), neuroborreliosis (NB) and other neurological diseases; Kruskal-Wallis-test $p < 0.001$, pair wise comparisons (Mann-Whitney U-test) $p < 0.01$; for explanation of abbreviations see Figure 1.

Figure 3: CSF CXCL13 in neuroborreliosis patients prior to therapy plotted against time since onset of symptoms (time to lumbar puncture). Straight line is regression line; correlation was significant ($p = 0.044$, $R = -0.383$).

Figure 4: Relative changes (median and IQR) in CSF CXCL13, leukocyte count, Q(albumin) (CSF/serum albumin concentration ratio) and BB-IgG-AI over follow-up in 25 patients with neuroborreliosis.

CSF-CXCL13 [ng/g protein]



Serum-CXCL13 [pg/ml]

